能倍乐的使用效果

Sliva is a drug developed by Boehringer Ingelheim. It has been approved for marketing in my country. Its indication is the treatment of adult chronic obstructive pulmonary disease (COPD). It can effectively improve the quality of life of COPD patients and reduce acute exacerbations of COPD.

Chronic obstructive pulmonary disease is a type of chronic bronchitis and/or emphysema characterized by airflow obstruction, which can further develop into common chronic diseases such as cor pulmonale and respiratory failure. It is related to the abnormal inflammatory response of harmful gases and harmful particles, resulting in high disability and mortality rates. The launch of Respimat has brought new hope for the treatment of COPD patients.

Effects of using Respimat:

Respimat is a long-acting anticholinergic drug with similar affinity for the five cholinergic receptors (M1-M5). It dilates bronchial smooth muscle by binding to M3 receptors on smooth muscle. This effect is competitive and reversible. In vivo and in vitro studies have shown that Respimat has a dose-dependent and sustainable 24-hour inhibition of methacholine-induced bronchoconstriction. Respimat's bronchial dilation effect has outstanding localization selectivity.

The approval of Spirava Respimat was based on data from two pivotal Phase III trials (TONADO-1, -2). The study involved more than 5,000 COPD patients. Data showed that compared with placebo, tiotropium bromide, and olodaterol monotherapy, Respimat produced a statistically significant improvement in patients' lung function (FEV1) and had a similar safety profile to tiotropium bromide or olodaterol.

The above is the treatment effect. I hope it will be helpful to you. If you have other questions, please consult the medical companion passenger service for answers.

Recommended related hot articles: /newsDetail/82132.html